Interferon Alfa-2B

CHEMBL1201558 Phase 4 Approuvé Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
746.5 g/mol
LogP
Phase
4

This recombinant interferon protein boosts the immune system's natural antiviral and anticancer defenses. It has been used to treat chronic hepatitis B and C, hairy cell leukemia, melanoma, follicular lymphoma, and other conditions. Common side effects include fatigue, fever, and depression, and monitoring is required during treatment.

Masse moléculaire

746,5000 g/mol

TPSA

113,00 Ų

Aires thérapeutiques

Mécanisme d'action

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCCN(CCOC1=C(C=C(C=C1Cl)Cl)Cl)C(=O)N2C=CN=C2.C(S(=O)(=O)[O-])(I)I.[Na+]

InChI

InChI=1S/C15H16Cl3N3O2.CH2I2O3S.Na/c1-2-4-20(15(22)21-5-3-19-10-21)6-7-23-14-12(17)8-11(16)9-13(14)18;2-1(3)7(4,5)6;/h3,5,8-10H,2,4,6-7H2,1H3;1H,(H,4,5,6);/q;;+1/p-1

Molecular Formula

C16H17Cl3I2N3NaO5S

HBD / HBA

- / 6

Liaisons Rotatives

7

Atomes Lourds

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This recombinant interferon protein boosts the immune system's natural antiviral and anticancer defenses. It has been used to treat chronic hepatitis B and C, hairy cell leukemia, melanoma, follicular lymphoma, and other conditions. Common side effects include fatigue, fever, and depression, and monitoring is required during treatment.

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Yes, Interferon Alfa-2B is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201558. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 71306834. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.